by David M. McIntosh
Washington Legal Foundation
July 01, 2004
Thanks to its superficial appeal and popularity with the public, politicians and media pundits have embraced the concept of allowing "reimportation" of pharmaceutical products produced here but sold abroad as a way of alleviating the alleged increased cost of health care. But as this paper argues, recent finds recent congressional proposals advancing reimportation are to short-sighted cures which will ultimately harm those very Americans whose lives will someday depend on investment in biotechnology to create the next medical miracles.

Heritage FoundationInsiderOnline is a product of The Heritage Foundation.
214 Massachusetts Avenue NE | Washington DC 20002-4999
ph 202.546.4400 | fax 202.546.8328
© 1995 - 2015 The Heritage Foundation